Anastrozole is a prescription tablet that lowers the amount of estrogen in the body. It is prescribed mainly to postmenopausal women with hormone receptor-positive breast cancer, either after surgery or for advanced disease. It belongs to a drug class called aromatase inhibitors, and it is sold both as the brand Arimidex and as a generic tablet.
This page explains what the medicine does, what the official label supports, the effects people report most often, the warnings that change what a clinician monitors, and what drives the cash cost of a month of treatment. It is a plain-English reference, not treatment advice for your situation.
How anastrozole lowers estrogen
Estrogen is made in more than one place. Before menopause, the ovaries produce most of it. After menopause, the ovaries mostly stop, and the body makes small amounts of estrogen elsewhere: in fat tissue, muscle, skin and the breast itself.
That backup production depends on an enzyme called aromatase. Aromatase converts androgens, the hormones often called male-type hormones, into estrogen. Anastrozole blocks that enzyme. In a postmenopausal body, blocking aromatase cuts circulating estrogen sharply, because there is no ovarian supply left to make up the difference.
Why does that matter for cancer? Hormone receptor-positive breast cancer cells carry receptors that respond to estrogen and use it as a growth signal. Remove most of the estrogen and you remove much of the signal. The drug does not kill tumor cells directly. It starves them of fuel. The National Cancer Institute describes this hormone therapy approach in similar plain terms.
This mechanism also explains the label’s limits. In a premenopausal body, the ovaries can respond to falling estrogen by making more, so an aromatase inhibitor used alone is not the right tool. When these drugs are used before menopause, they are combined with treatment that shuts down ovarian function, and that is a specialist decision. The same mechanism explains most of the side effects: very low estrogen feels like an intense version of menopause.
What the FDA label approves it for
The label is narrower than search results often suggest. Approved uses cover postmenopausal women only, in three settings: added treatment after surgery for early hormone receptor-positive breast cancer; first-line treatment of locally advanced or metastatic disease that is hormone receptor-positive or hormone receptor unknown; and advanced disease that has progressed after tamoxifen. The label also notes that women with ER-negative disease, and those who did not respond to tamoxifen before, rarely responded to this drug. Full prescribing information is published through the National Library of Medicine’s DailyMed label database.
The approved dose is simple by design: one 1 mg tablet by mouth once a day. The same dose applies across all three approved uses, and there is no titration schedule to climb. The tablet can be taken with or without food, which is why many people pick a fixed daily time and keep it. The medicine has not been studied in severe liver disease. If you miss a dose, ask the prescribing office or pharmacist what to do rather than doubling up on your own.
Treatment length is a separate question from dose. In the adjuvant trials that supported approval, women took the tablet for about five years, and some people continue longer based on their recurrence risk. That trade-off, more years of protection against more years of side effects, belongs to you and your oncology team. Patient-facing dosing context is also summarized by Mayo Clinic’s oral route drug page for this medicine.
Side effects people actually report
Most side effects trace back to low estrogen, and most are not dangerous, but they are real and they can wear people down over years.
- Hot flashes and night sweats. Among the most frequently reported effects in the large adjuvant trial, affecting roughly a third of women.
- Joint pain and stiffness. Also reported by roughly a third. It often shows up in the hands, knees, hips and feet, and it tends to be worst in the morning.
- Fatigue and weakness. Common, and often the effect people mention first in daily life.
- Mood changes, low mood and poor sleep. Reported regularly and worth raising early rather than tolerating quietly.
- Vaginal dryness and lower sex drive. Direct consequences of very low estrogen.
- Nausea, headache, rash, thinning hair, higher blood pressure and bone pain. All appear in the trial adverse reaction tables.
Comparative trial data on tolerability is summarized in a peer-reviewed review hosted on PubMed Central. Joint symptoms are a leading reason people stop early or switch to a different aromatase inhibitor, which is a conversation worth having before you quit on your own.
Does it cause weight gain?
Weight gain appears in adverse event lists, and plenty of people do gain weight during treatment. What the evidence does not show is a simple direct cause. Falling estrogen shifts where the body stores fat. Joint pain reduces activity. Chemotherapy, aging, and menopause itself all overlap with the same years. Treat weight change as something to track and discuss, not as proof the tablet is to blame or proof that it is not.
What changes after five years
Nothing new switches on at the five-year mark, but two things accumulate. Bone density loss builds quietly over time, which is why scans are repeated rather than done once. Joint and menopausal symptoms can persist for as long as you take the drug, and often ease within months of stopping. Cholesterol changes also tend to be tracked over years rather than weeks. Cancer centers such as Memorial Sloan Kettering publish patient medication summaries covering bone effects in ordinary language.
Warnings that change what gets monitored
Four label warnings drive most of the monitoring around this medicine, and each one has a practical consequence.
Heart disease history. In women who already had ischemic heart disease, more ischemic cardiovascular events occurred with this drug than with tamoxifen. If you have angina, a prior heart attack or known coronary disease, that history belongs in the conversation before the first prescription. Official warning text is available through the FDA’s Drugs@FDA approved labeling database.
Bone mineral density. Estrogen protects bone, so lowering it can thin bone over time. The label advises considering bone density monitoring, and more fractures occurred in trials than with tamoxifen. In practice that can mean a baseline scan, repeat scans, and a discussion about calcium, vitamin D, weight-bearing exercise or bone-protecting medicines.
Cholesterol. Total cholesterol can rise, so lipid checks may be added to routine bloodwork. Numbers on a lab report are easier to act on when you can see the ratios rather than one value in isolation.
Cholesterol ratio and LDL
Work out LDL and the total-to-HDL ratio from a standard lipid panel, the two numbers a clinician reads first.
Friedewald equation, which is unreliable when triglycerides exceed 400 mg/dL. Ratios are a screening signal, not a treatment decision.
Pregnancy risk. The drug can harm a fetus. Anyone who could become pregnant needs effective contraception and a clear plan discussed with their clinician. It is not for use in pregnancy or while breastfeeding.
Two more points sit outside those four. The medicine is contraindicated in anyone with a known hypersensitivity to it, and rare severe allergic and skin reactions have been reported after approval. Liver enzyme changes have also been reported. None of that is common, but all of it is worth recognizing rather than dismissing.
Interactions, alcohol and what to avoid
The interaction list is shorter than most people expect, and two entries matter most.
- Tamoxifen. Taking the two together lowers the level of the aromatase inhibitor in the blood, so they are not used at the same time.
- Estrogen-containing products. Estrogen therapy works against the whole point of the treatment. That includes hormone replacement therapy, some vaginal products and some supplements marketed for menopause symptoms. Ask before starting any of them.
At the approved dose, no major liver-enzyme drug interactions of the kind that plague other medicines have been established. That is not permission to skip the conversation. Give your prescriber and pharmacist a full list, including over-the-counter products, herbal remedies and hormone-adjacent supplements such as DHEA.
On food, the honest answer to a very common question is that the label sets no food restrictions. The tablet can be taken with or without food, and no grapefruit warning applies the way it does with some other drugs. Alcohol is not banned, though it can worsen hot flashes and sleep problems, and heavy drinking is not friendly to bone health. Soy foods generate a lot of argument online; the evidence is mixed, and it is a reasonable thing to ask your oncology team about rather than settle from a forum post. Patient dosing and food guidance is set out in the MedlinePlus consumer drug information entry.
Off-label use in men, and why it is different
Search interest in this drug for men is high, so the status needs to be plain: the label covers postmenopausal women. There is no FDA-approved use in men, and therefore no approved dose in men.
Clinicians do sometimes prescribe it off-label. The usual reasons are gynecomastia, low testosterone with a high estradiol level, or estrogen control alongside testosterone therapy. Off-label prescribing is legal and sometimes reasonable, but here it rests on small, short studies rather than the large trial base that supports the cancer indications.
The physiology cuts both ways. Men need estrogen too, particularly for bone density, and pushing estradiol too low can bring joint pain, low libido, mood changes and unfavorable effects on bone and lipids. That is the core argument for lab monitoring rather than fixed dosing by feel. Unsupervised use alongside anabolic steroids, which is where much of the bodybuilding interest comes from, removes both the monitoring and any assurance about what is in the product.
Some telemedicine men’s health programs include this medicine within a broader hormone program. If you are comparing them, look at what is actually included: which labs are drawn, how often they repeat, who the prescribing clinician is, and whether follow-up visits cost extra. Our Telehealth Provider Directory lists programs by condition and treatment type so you can see the models side by side.
Arimidex, generics and compounded versions
The medicine comes as one thing: a small oral tablet taken once a day. There is no injection, no patch and no approved topical form. Arimidex is the original brand. Multiple manufacturers now make generic versions.
Arimidex (Brand) vs. Generic Anastrozole
| Arimidex (Brand) | Generic Anastrozole | |
|---|---|---|
| Active ingredient | Same | Same |
| FDA review path | Original approval | Bioequivalence required |
| Tablet appearance | Fixed | Varies by manufacturer |
| Typical self-pay cost | Higher | Generally lower |
| Pharmacy stocking | Less common | Widely stocked |
| What differs | Arimidex (brand) | Generic anastrozole |
|---|---|---|
| Active ingredient | Same | Same |
| FDA review path | Original approval | Approved after showing bioequivalence |
| Tablet look and inactive ingredients | Fixed | Vary by manufacturer |
| Typical self-pay cost | Higher | Generally lower |
| Pharmacy stocking | Less common | Widely stocked |
Generic approval requires the same active ingredient, strength and route, and evidence that the body absorbs it the same way, as explained in the FDA’s overview of how generic drugs are approved. Switching between generic manufacturers is normal, though the tablet may change color or shape.
Compounded versions, including creams prepared by compounding pharmacies for some men’s hormone programs, sit in a different category. Compounded preparations are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold, even when the active ingredient itself is approved elsewhere. If a program offers one, ask which pharmacy prepares it, whether that pharmacy is a 503A or 503B facility, and why a compounded form is being used instead of the approved tablet. You can browse other compounds covered on this site through the Medication Reference Index.
Cost without insurance, and what moves the number
Two payment routes get tracked separately here, and mixing them produces nonsense. Cash pay is what a self-pay patient pays per month. The insurance route covers only the plan or membership fee, and it excludes copays and deductibles, which vary by plan and by state.
Most people taking this drug get it the ordinary way: an oncology team writes the prescription, and a retail or mail pharmacy fills it. In that setup the monthly cost is a pharmacy cost, not a subscription cost, and it varies by pharmacy more than most patients expect. Where a telehealth program is involved instead, the monthly membership and the medication are often billed as separate lines.
Lowest tracked self-pay monthly figure among programs listing this medicine:
Several things move a monthly cash figure: brand versus generic, which manufacturer your pharmacy stocks, whether you fill 30 days or 90 days at a time, whether labs are billed separately, whether a consultation or membership fee sits on top, and whether the product is a standard tablet or a compounded preparation. Advertised self-pay prices change often, so treat any figure as a snapshot rather than a fixed rate.
Insurance is its own puzzle. Generic tablets usually land on a low formulary tier, but that is a tendency, not a promise, and only your own plan document settles it. Ask about the tier, the copay, whether prior authorization applies, and whether mail order changes the number. Medicare drug coverage rules are explained on the official Medicare prescription drug coverage page. If you want to see the arithmetic over a full year rather than one refill, run it:
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
For a worked example of how monthly figures stack up across programs, see the Free Savings Report, and the wider set of Patient Cost Calculators covers dosing, lab and budgeting math.
How telehealth programs handle hormone-blocking prescriptions
If the reason for the prescription is breast cancer, care belongs with an oncology team. Telehealth can support that care with follow-up visits, symptom check-ins, refills or a second opinion, but it does not replace the specialist who set the plan.
Where telehealth plays a larger role is hormone management outside oncology, mostly in men’s health. Programs differ on points that matter more than the homepage design suggests:
- Who prescribes. Whether the clinician is named, their specialty, and whether you see the same person at follow-up.
- Labs. Which panels are required before the first prescription, how often they repeat, and whether the cost is bundled or added.
- Monitoring. Whether bone density, lipids and blood pressure are tracked, since those are the label’s monitoring concerns.
- Pharmacy. Whether you get an approved tablet from a licensed pharmacy or a compounded preparation, and which pharmacy fills it.
- What the monthly fee includes. Visits, messaging, dose changes and refills are sometimes bundled and sometimes not.
- State rules. Telemedicine prescribing and licensure requirements differ by state, so availability is not uniform nationwide.
How individual programs are rated across those dimensions is set out in our Scoring Methodology Explained, and ongoing coverage of how these programs operate sits in our Editorial Analysis.
Questions worth asking, and signs to act on
Bring a short list to the appointment. These tend to produce the most useful answers:
- Why this aromatase inhibitor rather than tamoxifen or a different one in the class?
- How long is treatment planned for, and when will we revisit that?
- Will I have a bone density scan, and how often will it repeat?
- Should my cholesterol and blood pressure be checked on a schedule?
- I have a heart condition. How does that change the risk and benefit for me?
- What should I do if joint pain makes daily activity hard? Is switching an option?
- Which supplements, hormone products and menopause remedies should I avoid?
- What is the generic situation at my pharmacy, and does a 90-day fill change my cost?
Some symptoms should not wait for the next scheduled visit. Get urgent medical help for chest pain, pressure or sudden shortness of breath; for signs of a serious allergic reaction such as swelling of the face, lips or throat, hives or trouble breathing; for a widespread blistering or peeling rash; for sudden severe bone pain or a fracture after minor injury; for yellowing of the skin or eyes; or for unusual vaginal bleeding. Call the prescribing office sooner rather than later about persistent low mood, since that is treatable and often goes unreported.
Questions to Ask Before Starting Anastrozole
- Why this aromatase inhibitor rather than tamoxifen or a different one?
- How long is treatment planned, and when will we revisit that?
- Will I have a bone density scan, and how often will it repeat?
- Should cholesterol and blood pressure be checked on a schedule?
- I have a heart condition, how does that change the risk and benefit?
- What supplements, hormone products, and menopause remedies should I avoid?
- Does a 90-day fill change my pharmacy cost?
Authoritative sources
- Treatment context and what to expect from this class of hormone therapy, from Breastcancer.org’s page on this aromatase inhibitor.
- Patient-facing hormonal therapy guidance published by Living Beyond Breast Cancer.
- Approved products and generic equivalence listings in the FDA Orange Book.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.
